Page last updated: 2024-12-05

cyclopentanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cyclopentanol is a cyclic alcohol with the formula C5H10O. It is a colorless liquid with a pungent odor. Cyclopentanol is used as a solvent and as an intermediate in the synthesis of other chemicals. Cyclopentanol can be synthesized by the reduction of cyclopentanone. Cyclopentanol is a common intermediate in the synthesis of various pharmaceutical compounds, such as anti-inflammatory drugs. It is also studied for its potential to be used as a renewable fuel. Cyclopentanol is also used as a solvent in the production of polymers and resins.'

Cross-References

ID SourceID
PubMed CID7298
CHEMBL ID288998
CHEBI ID16133
MeSH IDM0066263

Synonyms (55)

Synonym
bdbm36176
CHEBI:16133 ,
hydroxycyclopentane
nsc49117
nsc-49117
NCGC00091006-01
smr000673565
MLS001055338
cyclopentyl alcohol
cyclopentanol ,
C02020
96-41-3
cyclopentanol, 99%
nsc 49117
hsdb 2821
einecs 202-504-8
un2244
ai3-25264
inchi=1/c5h10o/c6-5-3-1-2-4-5/h5-6h,1-4h
CHEMBL288998
AKOS000118901
A845587
NCGC00091006-02
1-cyclopentanol
unii-1l43q07tbu
cyclopentanol [un2244] [flammable liquid]
1l43q07tbu ,
ec 202-504-8
YEG ,
HMS3039M14
dtxcid9013371
NCGC00257249-01
dtxsid1033371 ,
tox21_303563
cas-96-41-3
NCGC00257663-01
tox21_200109
STL280357
FT-0624258
FT-0624257
un-2244
cyclopentanol [mi]
un 2244
cydopentanol
1-cyclopentyl alcohol
STR07441
mfcd00001363
F0001-2295
cyclopentanol, analytical standard
CS-W004073
Q284201
hydroxycyclopentane;cyclopentyl alcohol;1-cyclopentanol
BCP30892
AMY3616
EN300-19348
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclopentanolsAn alcohol in which one or more hydroxy groups are attached to a cyclopentane skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.28700.006038.004119,952.5996AID1159521
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.07940.001318.074339.8107AID926; AID938
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.58960.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency30.57560.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.33770.000229.305416,493.5996AID743069
activating transcription factor 6Homo sapiens (human)Potency17.50780.143427.612159.8106AID1159516; AID1159519
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID101345Toxicity determined using Golden Orfe Fish Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (8.82)18.7374
1990's6 (17.65)18.2507
2000's12 (35.29)29.6817
2010's10 (29.41)24.3611
2020's3 (8.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.74 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]